Acuta Capital Partners LLC Trims Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Acuta Capital Partners LLC cut its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 58.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 884,244 shares of the company's stock after selling 1,234,748 shares during the quarter. Taysha Gene Therapies makes up about 1.5% of Acuta Capital Partners LLC's holdings, making the stock its 22nd biggest holding. Acuta Capital Partners LLC owned 0.43% of Taysha Gene Therapies worth $1,530,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Hsbc Holdings PLC grew its holdings in Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after purchasing an additional 8,076 shares during the period. Virtus ETF Advisers LLC increased its position in Taysha Gene Therapies by 43.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company's stock valued at $55,000 after buying an additional 9,494 shares in the last quarter. Geode Capital Management LLC raised its stake in Taysha Gene Therapies by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock valued at $6,182,000 after buying an additional 9,591 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Taysha Gene Therapies by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock worth $820,000 after acquiring an additional 11,390 shares in the last quarter. Finally, Privium Fund Management B.V. grew its stake in shares of Taysha Gene Therapies by 12.4% in the fourth quarter. Privium Fund Management B.V. now owns 134,900 shares of the company's stock worth $233,000 after acquiring an additional 14,900 shares during the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on TSHA shares. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Chardan Capital restated a "buy" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $6.63.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA traded down $0.10 on Wednesday, hitting $1.91. The stock had a trading volume of 1,239,419 shares, compared to its average volume of 2,775,968. The business's 50-day simple moving average is $1.62 and its two-hundred day simple moving average is $1.80. The stock has a market cap of $390.63 million, a price-to-earnings ratio of 3.02 and a beta of 0.90. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $4.32. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. As a group, research analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.